Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting

VivoSim Labs, INC.

Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.
Lead asset FXR314, an oral FXR agonist for IBD, to be advanced to Phase 2 by Lilly.
Organovo faces Nasdaq delisting: stockholders' equity of $364K as of Dec 31, 2024, below $2.5M minimum.
Hearing before Nasdaq panel scheduled Feb 27, 2025; company may pursue reverse stock split to regain bid price compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.